The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $23.20. Guggenheim reissued a “buy” rating and set a $25.00 price target on shares of Immunome in a research note on Monday, August 25th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $21.00 target price on shares of Immunome in a research report on Thursday, September 18th. On average, equities research analysts anticipate that Immunome will post -2.21 EPS for the current fiscal year.